334 related articles for article (PubMed ID: 32103870)
21. GM101 in Combination with Histone Deacetylase Inhibitor Enhances Anti-Tumor Effects in Desmoplastic Microenvironment.
Chang HG; Choi YH; Hong J; Choi JW; Yoon AR; Yun CO
Cells; 2021 Oct; 10(11):. PubMed ID: 34831034
[TBL] [Abstract][Full Text] [Related]
22. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
[TBL] [Abstract][Full Text] [Related]
23. Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.
Newbold A; Matthews GM; Bots M; Cluse LA; Clarke CJ; Banks KM; Cullinane C; Bolden JE; Christiansen AJ; Dickins RA; Miccolo C; Chiocca S; Kral AM; Ozerova ND; Miller TA; Methot JL; Richon VM; Secrist JP; Minucci S; Johnstone RW
Mol Cancer Ther; 2013 Dec; 12(12):2709-21. PubMed ID: 24092806
[TBL] [Abstract][Full Text] [Related]
24. Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines.
Zhang X; Yashiro M; Ren J; Hirakawa K
Oncol Rep; 2006 Sep; 16(3):563-8. PubMed ID: 16865256
[TBL] [Abstract][Full Text] [Related]
25. Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: A proteomic approach.
Li QQ; Hao JJ; Zhang Z; Hsu I; Liu Y; Tao Z; Lewi K; Metwalli AR; Agarwal PK
Int J Oncol; 2016 Jun; 48(6):2591-607. PubMed ID: 27082124
[TBL] [Abstract][Full Text] [Related]
26. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
Santini V; Gozzini A; Ferrari G
Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
[TBL] [Abstract][Full Text] [Related]
27. Histone Deacetylase Inhibitors as Anticancer Drugs.
Eckschlager T; Plch J; Stiborova M; Hrabeta J
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
[TBL] [Abstract][Full Text] [Related]
28. Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cells.
Venturelli S; Berger A; Böcker A; Busch C; Weiland T; Noor S; Leischner C; Schleicher S; Mayer M; Weiss TS; Bischoff SC; Lauer UM; Bitzer M
PLoS One; 2013; 8(8):e73097. PubMed ID: 24023672
[TBL] [Abstract][Full Text] [Related]
29. Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells.
Cortiguera MG; García-Gaipo L; Wagner SD; León J; Batlle-López A; Delgado MD
Sci Rep; 2019 Nov; 9(1):16495. PubMed ID: 31712669
[TBL] [Abstract][Full Text] [Related]
30. Identification of HDAC9 as a viable therapeutic target for the treatment of gastric cancer.
Xiong K; Zhang H; Du Y; Tian J; Ding S
Exp Mol Med; 2019 Aug; 51(8):1-15. PubMed ID: 31451695
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of mTOR signalling potentiates the effects of trichostatin A in human gastric cancer cell lines by promoting histone acetylation.
Sun DF; Zhang YJ; Tian XQ; Chen YX; Fang JY
Cell Biol Int; 2014 Jan; 38(1):50-63. PubMed ID: 24030871
[TBL] [Abstract][Full Text] [Related]
32. 4-phenylbutyric acid promotes migration of gastric cancer cells by histone deacetylase inhibition-mediated IL-8 upregulation.
Shi X; Gong L; Liu Y; Hou K; Fan Y; Li C; Wen T; Qu X; Che X
Epigenetics; 2020; 15(6-7):632-645. PubMed ID: 31814524
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis, and characterization of α, β-unsaturated carboxylic acid, and its urea based derivatives that explores novel epigenetic modulators in human non-small cell lung cancer A549 cell line.
Chidambaram A; Sundararaju K; Chidambaram RK; Subbiah R; Jayaraj JM; Muthusamy K; Vilwanathan R
J Cell Physiol; 2018 Jul; 233(7):5293-5309. PubMed ID: 29215703
[TBL] [Abstract][Full Text] [Related]
34. Prospects: histone deacetylase inhibitors.
Dokmanovic M; Marks PA
J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937
[TBL] [Abstract][Full Text] [Related]
35. Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma.
Andrews JM; Schmidt JA; Carson KR; Musiek AC; Mehta-Shah N; Payton JE
EBioMedicine; 2019 Aug; 46():170-183. PubMed ID: 31358475
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylase inhibitors in cancer therapy.
Rasheed WK; Johnstone RW; Prince HM
Expert Opin Investig Drugs; 2007 May; 16(5):659-78. PubMed ID: 17461739
[TBL] [Abstract][Full Text] [Related]
37. RNH1 regulation of reactive oxygen species contributes to histone deacetylase inhibitor resistance in gastric cancer cells.
Zhu Y; Das K; Wu J; Lee MH; Tan P
Oncogene; 2014 Mar; 33(12):1527-37. PubMed ID: 23584480
[TBL] [Abstract][Full Text] [Related]
38. Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.
Rivera-Del Valle N; Cheng T; Irwin ME; Donnella H; Singh MM; Chandra J
Cancer Chemother Pharmacol; 2018 Mar; 81(3):483-495. PubMed ID: 29313067
[TBL] [Abstract][Full Text] [Related]
39. Molecular docking of curcumin and curcuminoids as human Zn
Anandaradje A; Kalita B; Coumar MS; Selvarajan S
In Silico Pharmacol; 2024; 12(1):47. PubMed ID: 38817777
[TBL] [Abstract][Full Text] [Related]
40. Epigenetically maintained SW13+ and SW13- subtypes have different oncogenic potential and convert with HDAC1 inhibition.
Davis MR; Daggett JJ; Pascual AS; Lam JM; Leyva KJ; Cooper KE; Hull EE
BMC Cancer; 2016 May; 16():316. PubMed ID: 27188282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
